Nogapendekin alfa inbakicept - Altor BioScience Corporation
Alternative Names: ALT 803; ANKTIVA; IL-15N72D/IL-15Ra-Fc - Altor BioScience Corporation; IL-15N72D:IL-15RαSu/Fc fusion protein complex; IL-15sa - Altor BioScience Corporation; Interleukin 15 superagonist - Altor BioScience Corporation; N-803; Nogapendekin alfa inbakicept - ImmunityBio; Nogapendekin alfa inbakicept-pmln - Altor BioScience Corporation; Superagonist Interleukin-15:Interleukin-15 receptor alphaSu/Fc Fusion complex - Altor BioScience Corporation; VesAnktiva™Latest Information Update: 28 Sep 2024
At a glance
- Originator Altor BioScience Corporation
- Developer Altor BioScience Corporation; ImmunityBio; National Cancer Institute (USA)
- Class Antineoplastics; Antiretrovirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Bladder cancer
- Phase III Non-small cell lung cancer
- Phase II Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Phase I/II Endometrial cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Triple negative breast cancer
- No development reported COVID 2019 infections; HIV-1 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (Parenteral)
- 26 Sep 2024 Altor BioScience terminates phase I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (IV/SC) (NCT02099539)
- 09 Sep 2024 Efficacy and adverse events data from the QUILT 3.055 phase II trial in Non-small cell lung cancer released by ImmunityBio